Companies ›Healthcare ›COSM

COSM — Nasdaq Diversified Pharmaceuticals

Cosmos Health Inc.

$0,23

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

10,7M USD

P/E

—

EV / Rev

0,2x

Div yield

—

Op margin

-25,6 %

ROE

-96,6 %

Net margin

-29,3 %

Debt / equity

—

Beta

—

52w range

—

Volume

155,5k

Day range

$0,30–$0,35

Prev close

$0,29

Open

$0,30

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Cosmos Health Inc. operates as a software and IT services company, generating revenue through application software and related health-tech solutions, including distribution via Amazon UK.

Business. Cosmos Health Inc. (Nasdaq: COSM) is a software company that develops application software, primarily operating within the Technology sector's Software & IT Services industry. The firm utilizes a subscription-based revenue model to deliver its solutions. As specific operating segments and geographic breakdowns are not disclosed, the company is described at the industry level. Cosmos Health is headquartered in the United States and is primarily listed on the Nasdaq stock exchange.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

BlackRock Institutional Trust Company, N.A.

largest disclosed fund holder

Profitability→

-96,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning COSM.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,7 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Consumer Discretionary+0,4 %+7,7 %−0,2 %

Information Technology+0,3 %+7,8 %−0,3 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to COSM. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Peers
EarningsQ2 2026 earnings (expected)2026-08-28 · estimated · Salesforce (CRM)
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated · ServiceNow (NOW)
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Cosmos Health Inc. (Nasdaq: COSM) is a software company that develops application software, primarily operating within the Technology sector's Software & IT Services industry. The firm utilizes a subscription-based revenue model to deliver its solutions. As specific operating segments and geographic breakdowns are not disclosed, the company is described at the industry level. Cosmos Health is headquartered in the United States and is primarily listed on the Nasdaq stock exchange.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

Cosmos Health maintains a fragile capital structure characterized by high liquidity risk and significant dilution pressure. The company holds $514,702 in cash and equivalents against total liabilities of $42,542,652, resulting in a current ratio of 1.08, which sits at the lower bound of comfort ranges. The balance sheet includes $7,856,208 in lines of credit and $5,432,237 in convertible notes payable, alongside a derivative liability of $1,060,230. The diluted share count of 47,087,621 is materially higher than the basic count of 41,067,312, indicating substantial embedded dilution from convertible instruments and options.

Profitability remains deeply negative, with a net loss of $2,805,423 in Q1 2026, driving a return on equity of -96.56% and a return on assets of -30.7%. Gross profit of $1,381,171 on revenue of $17,927,892 yields a gross margin of approximately 7.7%, which is exceptionally low for the software sector, suggesting a business model heavily weighted toward low-margin distribution or hardware rather than pure software licensing. Operating income was -$2,184,179, and free cash flow was negative $1,078,465, reflecting ongoing cash burn despite minimal capital expenditures of $11,399.

Key takeaways

Liquidity is critically tight with a current ratio of 1.08 and only $514k in cash against $34M in current liabilities.
Dilution risk is high, with diluted shares 14.6% higher than basic shares due to convertible notes and options.
Profitability is negative with a -96.56% ROE and a gross margin of ~7.7%, inconsistent with pure software peers.
Going-concern warnings are present in filings, signaling substantial doubt about the company’s ability to continue operations.
Recent stock volatility (17% daily move) reflects speculative trading rather than fundamental improvement.

Bull / Bear case

Generated · model-assisted

BULL CASE · 5

Analysts project a 1,693.5% upside to a $4.50 target price, significantly exceeding the current market price of $0.25.

Free cash flow improved by 4.3% year-over-year in FY2025, indicating a slight reduction in cash burn relative to the prior period.

The company maintains a zero debt-to-equity ratio, placing it above the median leverage level of its software cohort peers.

Operating income improved by 6.9% year-over-year in FY2025, suggesting a marginal stabilization in core operational profitability metrics.

Capital expenditure as a percentage of revenue is in the top quartile, indicating disciplined investment levels relative to peers.

BEAR CASE · 3

The company faces high dilution and liquidity risks, posing significant threats to shareholder value and operational continuity.

The company generated negative free cash flow of $8.5 million in FY2025, continuing its pattern of cash consumption.

Cash conversion of 0.44 is below the cohort median of 0.91, indicating inefficient translation of earnings into cash.

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Revenue $17.9M; Operating income -$2.2M.

Revenue$17.9M

Operating income-$2.2M

Net income-$2.8M

Free cash flow-$1.1M

EPS—

Operating cash flow-$1.1M

Financials

Income statement

Revenue$17.9M

Gross profit$1.4M

Operating income-$2.2M

Net income-$2.8M

Margins

Gross margin7.7%

Operating margin-12.2%

Net margin-15.6%

FCF margin-6.0%

Balance sheet

Total assets$62.4M

Total liabilities$42.5M

Total equity$19.8M

Cash & equivalents$514.7k

Long-term debt—

Cash flow

Operating cash flow-$1.1M

CapEx$11.4k

Free cash flow-$1.1M

SBC$535.8k

P&L flow · revenue → net income

Highlights

▍Revenue $17.9M
▍Operating income -$2.2M
▍Net margin -15.6%

Valuation FY

Market price

$0,23

Market cap

$12.1M

Enterprise valueⓘ

$11.6M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

0.2x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

0.9x

P / Tangible bookⓘ

0.9x

Tangible book

$13.0M

Net cashⓘ

$548.9k

Current ratioⓘ

1.1

Debt / equityⓘ

—

ROAⓘ

-30.7%

ROEⓘ

-96.6%

Cash conversionⓘ

44.0%

CapEx / revenueⓘ

0.1%

SBC / revenueⓘ

3.5%

Dilution ratioⓘ

14.7%

Revenue by segment

Branded Prescription Pharmaceuticals—

low · business_description · 2026-07-04

Generic Pharmaceuticals—

low · business_description · 2026-07-04

Nutraceuticals & Vitamins—

low · business_description · 2026-07-04

Business relationships

Business relationships4 disclosed relationships · 2 types · extracted from filings & disclosures

Partners1

Amazon.Com IncAMZN.OPartner90%

Competitors3

MICROSOFT CORPORATIONMSFT.OCompetitor50%

Salesforce IncCRM.OCompetitor50%

Servicenow IncNOW.OCompetitor50%

Supply chain

Vendors → COSM ↔ Partners → Customers · click any node to drill

0 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-07-08

Peer comparison

Peer comparison8 peers · vs COSM · multiples and returns

MCK—

Mckesson Corp

$829,00

102,9B USD

P/E

21,2x

— vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

-122,7 vs self

COR—

Cencora Inc

$312,00

60,9B USD

P/E

36,4x

— vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

+142,3 vs self

CAH—

Cardinal Health Inc

$235,33

56,9B USD

P/E

36,7x

— vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

+40,6 vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$758,42

81,0B USD

P/E

15,5x

— vs self

Div yield

—

— vs self

ROE

14,2 %

+110,8 vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

— vs self

Div yield

—

— vs self

ROE

7,5 %

+104,1 vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,84

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 23 %

EPS

Consensus EPS

0,01

Predicted surprise

-0,08

Beat probability

23 %

Analysts

—

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

revision ratio -0,88 · as of 2026-07-13 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,01
Revenue	—no estimate	—no estimate	87,3M USD
Operating income	—no estimate	—no estimate	—no estimate

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

12-month price target$4,50 · Median $4,50

Low $4,50High $4,50

EPS surprise

−6 400,0 %

reported vs consensus · miss

Revenue surprise

−25,2 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,50

Mean$4,50

Median$4,50

High$4,50

Spot$0,23

+1882.4 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskHigh

Liquidity riskHigh

Filing-based flags

Diluted share count is materially above the basic share count.
Current ratio is close to the minimum comfort range.
Filings reference going-concern or substantial-doubt language.
Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-25,6 %Below median

Net Margin-29,3 %Below median

ROE-96,6 %Bottom quartile

Capex / Rev0,1 %Above P75

D/E0,00Above median

Cash Conv0,44Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 3 302 000 sh7 transactions7 insiders

Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Restricted Stock Unit → Common Stock, par value $.001Disposed 2 350 000conversion · 2026-05-19
Demetriades Demetrios G.Director, Secretary · Restricted Stock Unit → Common Stock, par value $.001Disposed 20 000conversion · 2026-05-19
Aslidis AnastasiosDirector · Restricted Stock Unit → Common Stock, par value $.001Disposed 40 000conversion · 2026-05-19
Bhutawala SuhelDirector · Restricted Stock Unit → Common Stock, par value $.001Disposed 20 000conversion · 2026-05-19
Terzis GeorgiosChief Financial Officer · Restricted Stock Unit → Common Stock, par value $.001Disposed 850 000conversion · 2026-05-19
Karkantzos Theodoros ChristosDirector · Restricted Stock Unit → Common Stock, par value $.001Disposed 2 000conversion · 2026-05-19
Hoidas John JamesDirector · Restricted Stock Unit → Common Stock, par value $.001Disposed 20 000conversion · 2026-05-19

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Return On Assets
net_income / total_assets
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Enterprise Value
market_cap - net_cash
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)

Source documents

Cosmos Health Inc. company facts · 2026-07-08
Cosmos Health Inc. 10-Q 2026-05-20 · 2026-07-08
Cosmos Health Inc. 10-K 2026-04-15 · 2026-07-08
Cosmos Health Inc. 10-Q 2025-11-14 · 2026-07-08
Cosmos Health Inc. 10-Q 2025-08-18 · 2026-07-08
ha_price_move fired on COSM · 2026-07-08
Cosmos Health Inc. HA canonical relationships · 2026-07-08

Ownership & reference

Top holders

BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Grigorios SiokasChairman of the Board, Chief Executive Officer

Insider activity

Net buying11 buys · 0 sellsnet $1,2M7 insiders · last 365d

Terzis GeorgiosChief Financial Officer · Common Stock, par value $.001Bought 168 135 @ $0,25$42K · 2026-06-16
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 218 447 @ $0,21$45K · 2026-06-11
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 701 447 @ $0,23$160K · 2026-06-10
Demetriades Demetrios G.Director, Secretary · Common Stock, par value $.001Other 20 000 @ $0,28$6K · 2026-05-19
Hoidas John JamesDirector · Common Stock, par value $.001Other 20 000 @ $0,28$6K · 2026-05-19
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Other 2 350 000 @ $0,28$665K · 2026-05-19
Karkantzos Theodoros ChristosDirector · Common Stock, par value $.001Other 20 000 @ $0,28$6K · 2026-05-19
Terzis GeorgiosChief Financial Officer · Common Stock, par value $.001Other 850 000 @ $0,28$241K · 2026-05-19
Bhutawala SuhelDirector · Common Stock, par value $.001Other 20 000 @ $0,28$6K · 2026-05-19
Aslidis AnastasiosDirector · Common Stock, par value $.001Other 40 000 @ $0,28$11K · 2026-05-19
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 388 532 @ $0,37$145K · 2026-02-12
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 291 262 @ $0,41$120K · 2026-02-11
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 90 325 @ $0,50$45K · 2026-01-23
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 353 321 @ $0,50$175K · 2026-01-20
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 493 495 @ $0,45$220K · 2026-01-14
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 113 185 @ $0,50$57K · 2026-01-12
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 156 190 @ $0,52$81K · 2026-01-08
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Bought 124 880 @ $0,52$65K · 2026-01-07
Karkantzos Theodoros ChristosDirector · Common Stock, par value $.001Other 15 000 @ $0,00$15 · 2025-12-31
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Other 1 350 000 @ $0,00$1K · 2025-12-31
Siokas GrigoriosDirector, Chief Executive Officer, 10% owner · Common Stock, par value $.001Other 100 000 @ $0,00$100 · 2025-12-31
Terzis GeorgiosChief Financial Officer · Common Stock, par value $.001Other 490 000 @ $0,00$490 · 2025-12-31
Aslidis AnastasiosDirector · Common Stock, par value $.001Other 20 000 @ $0,00$20 · 2025-12-31
Hoidas John JamesDirector · Common Stock, par value $.001Other 15 000 @ $0,00$15 · 2025-12-31
Demetriades Demetrios G.Director, Secretary · Common Stock, par value $.001Other 15 000 @ $0,00$15 · 2025-12-31

Short positioning

5.6Mshares short+17.9% vs prior

1days to cover

45.3%short of daily vol

898.0Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

COSMCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob23 %Surprise-0,08Full forecast →

peak dispatch · —

OSINT findings

Dilution riskHigh

Liquidity riskHigh

Diluted share count is materially above the basic share count.

Current ratio is close to the minimum comfort range.

Filings reference going-concern or substantial-doubt language.

Source documents mention dilution or offering risk.

Relationship graph

This companyPeerSectorPartners

Evidence & claims

From filings & derived data

Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 58.0%Derived (calculated)
Net margin (FY 2025-12-31): -29.3%Derived (calculated)
Gross margin (FY 2025-12-31): 12.1%Derived (calculated)
Return on equity (FY 2025-12-31): -103.9%Derived (calculated)
Return on assets (FY 2025-12-31): -29.2%Derived (calculated)
Current ratio (FY 2025-12-31): 1.00xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 2.55xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -86.7%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 127.1%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 14.5%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 46.2%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 46.2%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 83.1%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -8.1%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -18.3%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -9.5%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -7.5%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 19.9%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -24.9%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 20.6%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -2.6%Derived (calculated)
Capex (annual): USD 55.67KSEC XBRL filing
Cash & equivalents (annual): USD 715.67KSEC XBRL filing
Shareholders' equity (annual): USD 18.42MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-16 00:00 UTCINSIDER3 insider transactions — 2026-06 · net buy $247k

2026-06-16INSIDERTerzis Georgios bought 168.1k sh Common Stock, par value $.001 — Chief Financial Officer ~$42k

2026-06-11INSIDERSiokas Grigorios bought 218.4k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$45k

2026-06-10INSIDERSiokas Grigorios bought 701.4k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$160k

2026-06-02FILINGDEF 14A filing →

2026-05-22FILINGFORM 8-K →

2026-05-20FILINGFORM 10-Q →

2026-05-19 00:00 UTCINSIDER14 insider transactions — 2026-05 · net buy $940k 7 derivative

2026-05-19INSIDERDemetriades Demetrios G. transacted 20.0k sh Common Stock, par value $.001 — Director, Secretary ~$6k

2026-05-19INSIDERHoidas John James transacted 20.0k sh Common Stock, par value $.001 — Director ~$6k

2026-05-19INSIDERSiokas Grigorios transacted 2.35M sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$665k

2026-05-19INSIDERKarkantzos Theodoros Christos transacted 20.0k sh Common Stock, par value $.001 — Director ~$6k

2026-05-19INSIDERTerzis Georgios transacted 850.0k sh Common Stock, par value $.001 — Chief Financial Officer ~$241k

2026-05-19INSIDERBhutawala Suhel transacted 20.0k sh Common Stock, par value $.001 — Director ~$6k

2026-05-19INSIDERAslidis Anastasios transacted 40.0k sh Common Stock, par value $.001 — Director ~$11k

2026-05-19INSIDERSiokas Grigorios disposed of 2.35M sh Restricted Stock Unit — Director, Chief Executive Officer, 10% owner

2026-05-19INSIDERDemetriades Demetrios G. disposed of 20.0k sh Restricted Stock Unit — Director, Secretary

2026-05-19INSIDERAslidis Anastasios disposed of 40.0k sh Restricted Stock Unit — Director

2026-05-19INSIDERBhutawala Suhel disposed of 20.0k sh Restricted Stock Unit — Director

2026-05-19INSIDERTerzis Georgios disposed of 850.0k sh Restricted Stock Unit — Chief Financial Officer

2026-05-19INSIDERKarkantzos Theodoros Christos disposed of 35.0k sh Restricted Stock Unit — Director

2026-05-19INSIDERHoidas John James disposed of 20.0k sh Restricted Stock Unit — Director

2026-04-16FILINGFORM 8-K →

2026-04-15FILINGFORM 10-K →

2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 17.9M · Net USD -2.8M

2026-02-12 00:00 UTCINSIDER2 insider transactions — 2026-02 · net buy $265k

2026-02-12INSIDERSiokas Grigorios bought 388.5k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$145k

2026-02-11INSIDERSiokas Grigorios bought 291.3k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$120k

2026-01-23 00:00 UTCINSIDER6 insider transactions — 2026-01 · net buy $643k

2026-01-23INSIDERSiokas Grigorios bought 90.3k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$45k

2026-01-20INSIDERSiokas Grigorios bought 353.3k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$175k

2026-01-14INSIDERSiokas Grigorios bought 493.5k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$220k

2026-01-12INSIDERSiokas Grigorios bought 113.2k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$57k

2026-01-08INSIDERSiokas Grigorios bought 156.2k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$81k

2026-01-07INSIDERSiokas Grigorios bought 124.9k sh Common Stock, par value $.001 — Director, Chief Executive Officer, 10% owner ~$65k

2025-12-31 00:00 UTCINSIDER8 insider transactions — 2025-12

2025-12-31EARNINGSQuarterly results — Q3 2025

2025-12-31EARNINGSAnnual results — FY 2025 Revenue USD 65.3M · Net USD -19.1M

Showing the 40 most recent of 58 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread